Hutchison China MediTech (Chi-Med) has started a China Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with epidermal growth factor receptor gene amplification. Epitinib is a selective oral EGFR inhibitor that is able to cross the blood-brain barrier. It is also expected to start a Phase III trial this year in patients with non-small cell lung cancer who have brain metastases. Chi-Med says glioblastoma is a primary brain cancer with high levels of EGFR gene amplification. More details....
Stock Symbol: (AIM/NSDQ: HCM)
Share this with colleagues:
Original Article: Chi-Med Starts China Trial of Epitinib in Glioblastoma Patients